Topic

Partner at Simon-Kucher & Partners, leading its life sciences division in greater China

Articles

Its use enables key processes such as early access, regulatory approval, and reimbursement listing.

Real-World Evidence Is Becoming a Pivotal Component in Chinese Healthcare

Senior Advisor to the FoCUS Project and Chief Clinical Officer for Real Endpoints

Upcoming regulatory changes to create new opportunity for specialized offerings.

Aligning Contracting to Solve for Payer Risks Is a Win for Biopharma, Payers, and Patients

William Borden is a freelance journalist covering the pharmaceutical industry. He is based in New Jersey.

Pharma and legal experts weigh in on the rush to secure intellectual property around psychedelic medicines, the value imperative that should govern pricing strategies, and the likely long-haul battle for more widespread decriminalization of these drugs.

A Complex Patent & Pricing Picture: Regulating Psychedelics More of a Journey Than a Trip 

Jill Wechsler is Pharm Exec's Washington Corespondent

As Congress struggles to reach agreement on funding for leading social and spending initiatives and to avoid default on government borrowing, the White House is emphasizing that reduced spending on prescription drugs can help offset some of the steep costs.

Drug Costs Central Issue in Budget Battles

The Democratic proposal to authorize price negotiations on costly medicines covered by Medicare and to penalize firms that raise prices faster than inflation has drawn opposition pharma and biotech companies. More surprisingly, generic companies also are objecting to the changes on the table.

Generics Makers Also Fight Price Controls

Bruce Liu leads Simon-Kucher’s Life Sciences division in Greater China. He has over 20 years of experience in the life sciences industry and is recognized as a thought leader on key industry topics, with recent publications on medtech access trends, reimbursement listing outlooks, business model innovations, and globalization strategy.

Shiyi He is a consultant with extensive experience in health economics and payer strategies in China.

Ivy Jiang is a consultant with years of experience in China pharmaceutical pricing and access strategies.

Duo Xu is a consultant specialized in China pharma and healthcare industry with recent experience on NRDL renewals.

Selene Peng is a consultant with experience across diverse therapeutic areas, and recent experience on NRDL trends and outlook.

The 2021 National Reimbursement Drug List (NRDL) process has been unfolding in China since June this year, with several key themes emerging. Building on Simon-Kucher’s experience with the NRDL, the authors make three recommendations on negotiation strategies going into the process.


China 2021 National Reimbursement Drug List Outlook

Democratic leaders in the House and Senate appear to have reached a compromise on a relatively modest plan for controlling prices on certain prescription drugs.

Will Pharma Accept the Democrats’ Drug Pricing Deal – Or Continue to Fight Reform?

Bruce Liu is recognized as a thought leader on key industry topics, with recent publications on medtech access trends, reimbursement listing outlooks, business model innovations, and globalization strategy.

MBA from the University of Chicago, MSc in molecular biology from the University of Rochester, and BSc in biochemistry from Fudan University.

Tong Wang is a Senior Consultant in Simon-Kucher's Life Sciences division and is based in the Shanghai office. He has supported a breadth of projects, working with pharmaceutical and medical technology companies in the China and US markets. His experience includes launch strategies, P&MA strategies, reimbursement strategies, and market opportunity evaluation. MSc in bioengineering from Rice University and obtained his BSc in biomedical engineering from Shanghai Jiao Tong University.

 is a Senior Consultant with experience in a breadth of projects working with both pharmaceutical and medtech companies in US, EU and China markets. His experience includes launch strategy, P&MA strategy, reimbursement strategies and P&MA tool development. Ph.D. from The University of California, Los Angeles in Molecular Biology.

 is a Senior Consultant with experience in the pharmaceutical industry and healthcare policies. Her areas of specialty include pricing strategies, market access opportunities, as well as post-launch competitive positioning in China. Master's degree in public administration with major in policy research analysis from the University of Pittsburg and a Bachelor's degree in public health administration.

Volume-based procurement (VoBP) has been gathering momentum in China, both at national and regional levels. Major pharmaceutical players stand to see large impacts on their branded generics portfolio, and need to move fast to improve organizational and system readiness.

Improving Readiness for Volume-Based Procurement in China

Democrats failed to gain sufficient support this week to advance long-debated legislation to permit Medicare drug price negotiations. 

Pharma Blocks Democrats’ Drug Pricing Plan

Legislative proposals for curbing outlays on prescription drugs have moved to center stage, as Congress looks hard for ways to pay for costly initiatives to repair the nation’s infrastructure, offset global warming and expand health care programs.